Navigation Links
Comparision of overall survival for non-small cell lung cancer patients
Date:5/28/2010

CHICAGO, IL. (May 28, 2010)There's debate about the best treatment approach for patients with certain stages of non-small cell lung cancer (NSCLC), which accounts for about 80 percent of all lung cancers. Patients with early stages of NSCLC are typically treated with surgery, but those with stage IIIA present more of a challenge because they are such a diverse group. However, research from Fox Chase Cancer Center shows that patient's with stage IIIA NSCLC who receive surgery, lobectomy in particular, have increased overall survival compared to those who received chemoradiation alonethose receiving lobectomy plus chemoradation had survival rates that were higher than previously reported as well.

The research, led by Charu Aggarwal, M.D., M.P.H., Walter Scott, M.D., F.A.C.S., and George Simon, M.D., will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday June 6.

Stage IIIA presents challenges because patients classified at that level are such a diverse group. The common denominator is that cancer has spread to lymph nodes on the same side of the chest as the primary tumor, but beyond that, stage IIIA patients may have tumors of any size and may differ in the number and location of affected lymph nodes.

"In the past, patients with advanced stage lung cancer were treated either with surgery alone, chemotherapy alone, or radiation alone," says Aggarwal. "Scientists and clinicians found that adding radiation to chemotherapy improved survival, so concurrent chemotherapy and radiation together became the standard of care." Recent large, Phase III clinical trials showed that patients treated with chemoradiation followed by surgery were more likely to be disease-free than counterparts who received chemoradiation without surgery set the stage for Aggarwal's study.

Looking at data from 249 patients treated at Fox Chase for stage IIIA non-small cell lung cancer from 2000 through 2008, the research team divided patients into three groups based on the treatments they received: chemoradiation only, chemoradiation plus surgical removal of a lung (pneumonectomy), or chemoradiation plus surgical removal of only one lobe of the lung (lobectomy).

Biostatistician Brian Egleston, Ph.D., used a technique called propensity score analysis to balance the three groups in terms of age, gender, smoking status, physical condition, and other variables that could bias the results.

"After we adjusted for all those variables, we saw that patients who received surgery, lobectomy in particular, had increased overall survival compared to those who received chemoradiation alone," says Aggarwal. "We saw overall survival of 40 percent at five years for chemoradiation plus lobectomy, higher than seen with pneumonectomy."

Removing the entire lung, a more extensive procedure that poses a greater risk of post-operative complications, offered no additional survival benefit." This tells us that you don't have to put the patient through pneumonectomy; you might get superior outcomes with a smaller, safer operation," says Aggarwal, who received an ASCO Foundation Merit Award for this research.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Study shows modest improvement in advanced lung cancer overall survival rates
2. 3M Recognized for Overall Software Performance in KLAS Industry Survey
3. Research validates surgery alone offers reasonable overall survival for stage I SCLC
4. News brief: ALDH associated with worse overall survival in patients with pancreatic adenocarcinoma
5. Survey: Toyota owners maintain high overall satisfaction despite recalls
6. UCSF Tops Public Institutions in NIH Funding, Ranks Second Overall
7. DBLG Announces Release 1.0 of the HITECH Act Survival Guide: an Open Source Law Initiative
8. Intensive Insulin Therapy Wont Boost Septic Shock Survival
9. Vitamin D Linked to Survival in Lymphoma Patients
10. Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer
11. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: